An investment fund represented by Baker Botts on Thursday filed a breach of contract suit against the biopharmaceutical company Dendreon Pharmaceuticals in the Southern District of New York, arguing that Dendreon paid only $4 million of a $13 million agreement.
The plaintiff AMC Fund L.P. and Dendreon agreed in May 2022 that Dendreon would buy 2 million shares of Global Cord Blood Corp. from AMC at $6.50 per share, for a total purchase price of $13 million, Baker Botts partner Richard B. Harper wrote in the complaint.
